Recombinant multi-species B4GALNT2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine B4GALNT2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
B4GALNT2 catalyzes the last step in the biosynthesis of the human Sd(a) antigen through the addition of an N-acetylgalactosamine residue via a beta-1,4 linkage to a subterminal galactose residue substituted with an alpha-2,3-linked sialic acid. B4GALNT2 also catalyzes the last step in the biosynthesis of the Cad antigen (Montiel et al., 2003 [PubMed 12678917]).[supplied by OMIM, Mar 2008]
The Alternative Names of target: 4 N-acetylgalactosaminyltransferase 2,4-GalNAc transferase,4-N-acetylgalactosaminyltransferase,B4GALNT2,B4GALT,B4galnt2,Beta-1,Dlb-1,Dlb1,GALGT2,Galg2,Galgt2,Ggm3,Igf2bp1,Sd(a) beta-1,UDP-GalNAc:Neu5Aca2-3Galb-R b1
Go
to B4GALNT2 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP0409-Ag-1/ GM-Tg-hg-IP0409-Ag-2 | Human B4GALNT2 protein | Human |
| GM-Tg-rg-IP0409-Ag-1/ GM-Tg-rg-IP0409-Ag-2 | Rat B4GALNT2 protein | Rat |
| GM-Tg-mg-IP0409-Ag-1/ GM-Tg-mg-IP0409-Ag-2 | Mouse B4GALNT2 protein | Mouse |
| GM-Tg-cynog-IP0409-Ag-1/ GM-Tg-cynog-IP0409-Ag-2 | Cynomolgus/Rhesus macaque B4GALNT2 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP0409-Ag-1/ GM-Tg-felg-IP0409-Ag-2 | Feline B4GALNT2 protein | Feline |
| GM-Tg-cang-IP0409-Ag-1/ GM-Tg-cang-IP0409-Ag-2 | Canine B4GALNT2 protein | Canine |
| GM-Tg-bovg-IP0409-Ag-1/ GM-Tg-bovg-IP0409-Ag-2 | Bovine B4GALNT2 protein | Bovine |
| GM-Tg-equg-IP0409-Ag-1/ GM-Tg-equg-IP0409-Ag-2 | Equine B4GALNT2 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP0409-Ag-1/ GM-Tg-hg-IP0409-Ag-2;
GM-Tg-rg-IP0409-Ag-1/ GM-Tg-rg-IP0409-Ag-2;
GM-Tg-mg-IP0409-Ag-1/ GM-Tg-mg-IP0409-Ag-2; GM-Tg-cynog-IP0409-Ag-1/ GM-Tg-cynog-IP0409-Ag-2; GM-Tg-felg-IP0409-Ag-1/ GM-Tg-felg-IP0409-Ag-2; GM-Tg-cang-IP0409-Ag-1/ GM-Tg-cang-IP0409-Ag-2; GM-Tg-bovg-IP0409-Ag-1/ GM-Tg-bovg-IP0409-Ag-2; GM-Tg-equg-IP0409-Ag-1/ GM-Tg-equg-IP0409-Ag-2 |
| Products Name | B4GALNT2 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | B4GALNT2 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine B4GALNT2 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.